Introduction
============

Sudden sensorineural hearing loss (SSNHL) is defined as a hearing loss of over 30 dB in three sequential frequencies developing within 3 days. The annual incidence is about 5--20 out of 100,000 people. SSNHL was previously thought to be mostly idiopathic, as the cause was often unidentified. Several etiological hypotheses, including vascular insults, membrane breaks and viral cochleitis have been proposed ([@ref-24]). Of the hypothesized etiologies, vascular ischemia or occlusion is one of the most popular. The internal auditory artery supplies blood to the inner ear, which lacks collateral circulation ([@ref-24]). Previous studies have reported several cardiovascular risk factors for SSNHL. For example, the rates of diabetes mellitus (DM) and hypercholesteremia were higher in SSNHL patients than those in the control group ([@ref-1]). Metabolic syndrome increased the risk of SSNHL in Taiwan ([@ref-7]) and Korea ([@ref-15]). Studies also showed that the risk of stroke was higher in SSNHL patients ([@ref-18]; [@ref-22]) and vise versa ([@ref-21]).

Common carotid artery (CCA) intima-media thickness (IMT), measured via Doppler ultrasonography, has frequently been used as a surrogate marker of subclinical atherosclerosis in many epidemiological and interventional studies of cardiovascular and cerebrovascular diseases ([@ref-3]). However, the association between IMT and SSNHL has not been fully explored. Higher carotid IMT values were found in SSNHL patients ([@ref-25]; [@ref-28]), suggesting an association between subclinical atherosclerosis and SSNHL ([@ref-28]). However, IMT is affected by several factors. We previously reported an association between gender and carotid IMT ([@ref-34]). It remains unknown whether subclinical atherosclerosis of the carotid artery is associated with SSNHL in both males and females and whether IMT values are higher for both male and female SSNHL patients. Since the risk of stroke is one of the greatest concerns for SSNHL patients ([@ref-22]), it is vital to to explore the associations between carotid IMT and SSNHL using subgroup analyses.

Furthermore, the associations between cardiovascular risk factors and SSNHL treatment outcomes remain unclear. Hypertension (HTN) ([@ref-10]), DM ([@ref-35]), and thrombophilia risk factors ([@ref-26]) have been linked to poor SSNHL prognosis. However, one study found that cardiovascular risk factors did not influence SSNHL hearing recovery ([@ref-9]). Since carotid IMT has been reported as a stroke severity marker ([@ref-12]), the association between carotid IMT and SSNHL treatment outcomes should be further examined.

We aimed to explore the potential association between carotid IMT and SSNHL and to analyze whether the results differed by sex. Additionally, this is the first investigation of the associations between carotid IMT and SSNHL treatment outcomes.

Materials and Methods
=====================

Subjects
--------

We retrospectively enrolled idiopathic SSNHL patients admitted to Kaohsiung Chang Gung Memorial Hospital, Taiwan between September 2011 and December 2015. We also age- and sex-matched control subjects without a history of SSNHL from a neurological health examination center. All subjects underwent carotid Doppler ultrasonography. SSNHL was defined as a SSNHL ≥ 30 dB over at least three contiguous frequencies developed within 72 h. We excluded patients with SSNHL whose origins were known, such as retrocochlear lesions (detected by acoustic brainstem response and magnetic resonance imaging) and infectious or autoimmune disease (revealed by laboratory data). Bilateral SSNHL cases were also excluded from our study. All patients underwent SSNHL treatment, including the administration of intravenous corticosteroids (5 mg of dexamethasone every 6 h for 2 days, followed by 5 mg every 8 h for 2 days, and then 5 mg every 12 h for 1 day) and a plasma expander (500 mL of Dextran 40 (a low-molecular weight dextran) each day for 5 days). We recorded their clinical data, including age, sex, smoking status, DM or HTN history, total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol levels. The Institutional Review Board of Chang Gung Memorial Hospital reviewed and approved the study protocol (reference number: 201801815B0).

IMT measurement
---------------

The protocol for measuring carotid IMT has been previously described ([@ref-34]). A B-mode ultrasound system (Philips HDI 5000 System; ATL-Philips, Bothell, WA, USA) equipped with a 4--10 MHz linear array transducer was used to obtain longitudinal images of the common carotid artery. An ultrasound technologist blinded to all clinical information performed the examinations. Both the left and right CCA were routinely scanned along a 1-cm segment immediately proximal to the dilatation of the bifurcation plane. The images were transferred to a workstation and the IMT, defined as the distance between the interfaces of the lumen intima and media adventitia, was automatically measured using Q-LAB software (ATL-Philips, Amsterdam, Netherlands). All measurements were performed in a single-blinded fashion. The average carotid IMT was calculated as the mean of the left and right CCA IMT values. When evaluating the association between IMT and SSNHL, an average carotid IMT \<0.65 mm was defined as low and a value ≥0.65 mm was considered high ([@ref-33]).

Acoustic evaluation
-------------------

Audiometry was performed using a GSI 61 audiometer (Grason-Stadler, Eden Prairie, MN, USA) and TDH-50p earphones (Telephonics, Farmingdale, NY, USA) in a soundproof booth. The pure-tone average (PTA) was the mean of the thresholds at 500, 1,000, 2,000 and 4,000 Hz. SSNHL was defined as hearing loss without an air-bone gap at each tested frequency. The word recognition score (WRS) was also evaluated by calculating the percentage of correctly identified words from a list of phonetically balanced, monosyllabic words. Pre- and post-treatment audiometry refer to hearing tests performed on the day of admission and about 3 months after treatment commenced, respectively. Disease severity was evaluated using the affected ear's initial PTA and WRS values in addition to associated vertigo. The outcomes of SSNHL treatments were assessed by calculating the hearing gain and WRS change, which were defined as the difference in hearing thresholds and WRSs, respectively, between pre- and post-treatment audiometry. Additionally, Siegel's criteria ([@ref-30]) were used to evaluate the extent of hearing recovery.

Statistical analysis
--------------------

We used SPSS software for Windows (ver. 18.0; SPSS, Inc., Chicago, IL, USA) for statistical analyses. A *P-*value \< 0.05 was considered to reflect statistical significance. The data means (with standard deviations, SDs),medians (with interquartile ranges, IQRs), and percentages were presented. The Kolmogorov--Smirnov test was used to assess whether parameters were normally distributed. Continuous variables, including age, cholesterol (total, LDL and HDL) levels, and average carotid IMT were compared between the SSNHL and control groups using an independent *t*-test for parametrically distributed data (age, total cholesterol and LDL cholesterol) or the Mann--Whitney *U*-test for non-parametrically distributed data (HDL cholesterol and average IMT). Categorical variables, including sex, smoking status, DM or HTN history and high/low IMT, were compared using Pearson's chi-squared test or Fischer's exact test (the latter when any expected value was less than 5). The categorical variable effect sizes were expressed as odds ratios (ORs) with 95% confidence intervals (CIs), which were calculated in the cross tables of a chi-square test for univariate analyses. The adjusted ORs in multiple logistic regression analyses were calculated using stepwise selection for age, HTN, LDL cholesterol and high average IMT.

Results
=======

Carotid IMT in SSNHL and control subjects
-----------------------------------------

We enrolled a total of 80 subjects (40 males (50%) and 40 females (50%); mean (SD) age, 51.8 (12.6) years (range, 20--80 years)), including 47 SSNHL patients and 33 participants in the control group. Their clinical characteristics are shown in [Table 1](#table-1){ref-type="table"}. There were no significant between-group differences in sex or age. There were no significant differences in cardiovascular factors including smoking status, DM and HTN history, or lipid profiles (total, LDL and HDL cholesterol levels). However, SSNHL patients exhibited a significantly higher average carotid IMT (median, 0.65 mm; IQR, 0.55--0.83 mm) than in the control group (median, 0.58 mm; IQR, 0.55--0.64 mm) (*P* = 0.022). High carotid IMT (IMT ≥ 0.65 mm) was significantly more common in the SSNHL group (53.2%, 25 of 47) than the control group (21.2%, 7 of 33) (OR, 4.22; 95% CI \[1.53--11.61\]) (*P* = 0.004). After adjusting for age, HTN and LDL cholesterol, the multivariate analysis still showed an association between high carotid IMT and SSNHL, with an adjusted OR of 4.655 (95% CI \[1.348--16.076\], *P* = 0.015).
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###### Characteristics of SSNHL and control subjects.

SSNHL patients had significant higher average IMT value and more percentage of high average IMT (≥0.65 mm) than those in the control group. *P* values \<0.05 are considered statistically significant and are bolded.
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                                         SSNHL (*n* = 47)    Control (*n* = 33)   *P* Value   OR (95% CI)[^a^](#table-1fn2){ref-type="fn"}
  -------------------------------------- ------------------- -------------------- ----------- ----------------------------------------------
  Sex, *n* (%)                                                                                
  Male                                   23 (48.9%)          17 (51.5%)           0.820       0.90 \[0.37--2.20\]
  Female                                 24 (51.1%)          16 (48.9%)                       1 \[Reference\]
  Age, mean (SD), year                   53.5 (13.2)         49.4 (11.5)          0.146       
  Smoking, *n* (%)                                                                            
  Yes                                    7 (14.9%)           3 (9.1%)             0.512       1.75 \[0.42--7.33\]
  No                                     40 (85.1%)          30 (90.9%)                       1 \[Reference\]
  DM, *n* (%)                                                                                 
  Yes                                    9 (19.1%)           4 (12.1%)            0.402       1.72 \[0.48--6.13\]
  No                                     38 (80.9%)          29 (87.9%)                       1 \[Reference\]
  HTN, *n* (%)                                                                                
  Yes                                    17 (36.2%)          7 (21.2%)            0.151       2.10 \[0.76--5.87\]
  No                                     30 (63.8%)          26 (78.8%)                       1 \[Reference\]
  Total cholesterol, mean (SD), mg/dl    196.7 (36.3)        193 (32.9)           0.688       
  LDL cholesterol, mean (SD), mg/dl      121.5 (33.1)        108 (29.6)           0.117       
  HDL cholesterol, median (IQR), mg/dl   56 (49.25--68)      56 (46.5--71.5)      0.994       
  Average IMT, median (IQR), mm          0.65 (0.55--0.83)   0.58 (0.55--0.64)    **0.022**   
  Average IMT, *n* (%)                                                                        
  High (≥0.65 mm)                        25 (53.2%)          7 (21.2%)            **0.004**   4.22 \[1.53--11.61\]
  Low (\<0.65 mm)                        22 (46.8%)          26 (78.8%)                       1 \[Reference\]

**Notes:**

SSNHL, sudden sensorineural hearing loss; DM, diabetes mellitus; HTN, hypertension; LDL, low-density lipoprotein; HDL, high-density lipoprotein; IMT, intima-media thickness; OR, Odds ratio; CI, confident interval.

Crude OR in univariate analyses.

Carotid IMT in SSNHL and control subjects stratified by sex
-----------------------------------------------------------

We then compared the cardiovascular risk factors and carotid IMT values between SSNHL and control subjects stratified by sex ([Table 2](#table-2){ref-type="table"}). There was no significant difference in the number of subjects with a history of DM or HTN or in the total, LDL and HDL cholesterol levels between the SSNHL and control groups in females or males. However, a significantly higher average carotid IMT was evident in female SSNHL patients (median, 0.67 mm; IQR, 0.55--0.89 mm) compared to those in the control group (median, 0.56 mm; IQR, 0.55--0.63 mm) (*P* = 0.044). Likewise, significantly more female SSNHL patients had a higher IMT (54.2%, 13 of 24) compared to those in the control group (12.5%, 2 of 16; OR 8.27 (95% CI \[1.53--44.62\])) (*P* = 0.008). A high IMT was also linked to SSNHL in females after further adjusting for age, HTN and LDL cholesterol level in the multivariate analysis, with an adjusted OR of 9.818 (95% CI \[1.064--90.587\], *P* = 0.044). In contrast, the median IMT value for male SSNHL patients and the percentage of male SSNHL patients with high IMT values were not significantly different than those in the control group.

10.7717/peerj.9276/table-2

###### Characteristics of SSNHL and control subjects stratified by sex.

Female SSNHL patients had significant higher average IMT value and more percentage of high average IMT (≥0.65 mm) than those in the female control group. *P* values \<0.05 are considered statistically significant and are bolded.
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                                         SSNHL               Control             *P* Value   OR (95% CI)[^a^](#table-2fn3){ref-type="fn"}
  -------------------------------------- ------------------- ------------------- ----------- ----------------------------------------------
  Age, mean (SD), year                                                                       
  Female                                 53.6 (14.7)         47.6 (12.7)         0.167       
  Male                                   53.9 (11.7)         51 (10.3)           0.561       
  Smoking, *n* (%)                                                                           
  Male                                                                                       
  Yes                                    7 (30.4%)           3 (17.6%)           0.471       2.04 \[0.44--9.44\]
  No                                     16 (69.6%)          14 (82.4%)                      1 \[Reference\]
  DM, *n* (%)                                                                                
  Female                                                                                     
  Yes                                    4 (16.7%)           2 (12.5%)           1.000       1.40 \[0.22--8.72\]
  No                                     20 (83.3%)          14 (87.5%)                      1 \[Reference\]
  Male                                                                                       
  Yes                                    5 (21.7%)           2 (11.8%)           0.677       2.08 \[0.35--12.3\]
  No                                     18 (78.3%)          15 (88.2%)                      1 \[Reference\]
  HTN, *n* (%)                                                                               
  Female                                                                                     
  Yes                                    6 (25%)             3 (18.8%)           0.717       1.44 (0.3 to 6.87)
  No                                     18 (75%)            13 (81.2%)                      1 \[Reference\]
  Male                                                                                       
  Yes                                    11 (47.8%)          4 (23.5%)           0.117       2.98 (0.74 to 11.93)
  No                                     12 (52.2%)          13 (76.5%)                      1 \[Reference\]
  Total cholesterol, mean (SD), mg/dl                                                        
  Female                                 197.3 (34.7)        194.3 (38.7)        0.827       
  Male                                   196 (39)            192.1 (29.3)        0.754       
  LDL cholesterol, mean (SD), mg/dl                                                          
  Female                                 117.2 (36.5)        98 (28.1)           0.149       
  Male                                   126.2 (28.9)        117.1 (29.2)        0.406       
  HDL cholesterol, median (IQR), mg/dl                                                       
  Female                                 57 (53--69)         69 (47.5--94.25)    0.378       
  Male                                   53 (45.5--66)       51 (46--57)         0.812       
  Average IMT, median (IQR), mm                                                              
  Female                                 0.67 (0.55--0.89)   0.56 (0.55--0.63)   **0.044**   
  Male                                   0.65 (0.55--0.83)   0.60 (0.54--0.70)   0.194       
  Average IMT, *n* (%)                                                                       
  Female                                                                                     
  High (≥0.65 mm)                        13 (54.2%)          2 (12.5%)           **0.008**   8.27 \[1.53--44.6\])
  Low (\<0.65 mm)                        11 (45.8%)          14 (87.5%)                      1 \[Reference\]
  Male                                                                                       
  High (≥0.65 mm)                        12 (52.2%)          5 (29.4%)           **0.15**    2.62 \[0.70--9.86\]
  Low (\<0.65 mm)                        11 (47.8%)          12 (70.6%)                      1 \[Reference\]

**Notes:**

Smoking was not listed in females because all women were nonsmokers.

SSNHL, sudden sensorineural hearing loss; DM, diabetes mellitus; HTN, hypertension; LDL, low-density lipoprotein; HDL, high-density lipoprotein; IMT, intima-media thickness; OR, Odds ratio; CI, confident interval.

stratified by sex.

Carotid IMT in SSNHL and control group females of different ages
----------------------------------------------------------------

We further explored whether age influenced the association between IMT and SSNHL in females ([Table 3](#table-3){ref-type="table"}). In women ≥50 years of age, the common cardiovascular factor values did not differ between the SSNHL and control groups. However, among females aged ≥50 years, average carotid IMT values were significantly higher in SSNHL patients (median, 0.72 mm; IQR, 0.62--1.08 mm) than those in the control group (median, 0.63 mm; IQR, 0.58--0.64 mm) (*P* = 0.016). Likewise, the percentage of female patients ≥50 years with high IMT (75%, 12 of 16) was significantly greater in the SSNHL group than the control group (25%, 2 of 8; OR 9.0 (95% CI \[1.27--63.9\])) (*P* = 0.032). In contrast, the median IMT value for female SSNHL patients aged \<50 years and the proportion of female SSNHL patients aged \<50 years with IMT ≥0.65 mm did not differ significantly from those in the control group. The percentage of male SSNHL patients and control subjects with IMT ≥0.65 mm did not differ significantly among those aged ≥50 years or \<50 years.

10.7717/peerj.9276/table-3

###### Characteristics of female SSNHL and control subjects stratified by 50 years of age.

Female SSNHL patients ≥ 50 y/o had significant higher average IMT value and more percentage of high average IMT (≥ 0.65 mm) than those in the female control group ≥50 y/o. *P* values \< 0.05 are considered statistically significant and are bolded.
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                                         SSNHL               Control             *P* Value
  -------------------------------------- ------------------- ------------------- -----------
  Age, mean (SD), year                                                           
  ≥50 y/o                                62.2 (7.8)          56.9 (4.9)          0.095
  \<50 y/o                               38.4 (11.3)         37.5 (10.6)         0.875
  DM, *n* (%)                                                                    
  ≥50 y/o                                                                        
  Yes                                    4 (25%)             0 (0%)              0.262
  No                                     12 (75%)            8 (100%)            
  \<50 y/o                                                                       
  Yes                                    0 (0%)              2 (25%)             0.467
  No                                     8 (100%)            6 (75%)             
  HTN, *n* (%)                                                                   
  ≥50 y/o                                                                        
  Yes                                    6 (37.5%)           1 (12.5%)           0.352
  No                                     10 (62.5%)          7 (87.5%)           
  \<50 y/o                                                                       
  Yes                                    0 (0%)              2 (25%)             0.467
  No                                     8 (100%)            6 (75%)             
  Total cholesterol, mean (SD), mg/dl                                            
  ≥50 y/o                                194.3 (37.9)        182.8 (42.6)        0.574
  \<50 y/o                               202.8 (29.3)        205.8 (34.9)        0.873
  LDL cholesterol, mean (SD), mg/dl                                              
  ≥50 y/o                                116.1 (37.9)        96.2 (30.7)         0.304
  \<50 y/o                               119.4 (36.3)        99.8 (28.7)         0.331
  HDL cholesterol, median (IQR), mg/dl                                           
  ≥50 y/o                                57 (53--68)         68 (49.5--82)       0.382
  \<50 y/o                               58.5 (54.5--72)     70 (47--118.5)      0.769
  Average IMT, median (IQR), mm                                                  
  ≥50 y/o                                0.72 (0.62--1.08)   0.63 (0.58--0.64)   **0.016**
  \<50 y/o                               0.54 (0.47--0.59)   0.55 (0.48--0.56)   **0.752**
  Average IMT, *n* (%)                                                           
  ≥50 y/o                                                                        
  High (≥0.65 mm)                        12 (75%)            2 (25%)             **0.032**
  Low (\<0.65 mm)                        4 (25%)             6 (75%)             
  \<50 y/o                                                                       
  High (≥0.65 mm)                        7 (87.5%)           8 (100%)            1.000
  Low (\<0.65 mm)                        1 (12.5%)           0 (0%)              

**Note:**

SSNHL, sudden sensorineural hearing loss; DM, diabetes mellitus; HTN, hypertension; LDL, low-density lipoprotein; HDL, high-density lipoprotein; IMT, intima-media thickness; y/o, years old.

Disease severity and treatment outcomes between SSNHL patients with low and high IMT
------------------------------------------------------------------------------------

In terms of disease severity, the PTA and WRS of affected ears and associated vertigo symptoms did not differ significantly between the low and high IMT groups ([Table 4](#table-4){ref-type="table"}). The treatment outcomes, evaluated by hearing gain, WRS change and Siegel's criteria, did not differ significantly between the two groups ([Table 4](#table-4){ref-type="table"}). Disease severity and treatment outcomes also did not differ between the low and high IMT groups when we focused on either female or male subjects.

10.7717/peerj.9276/table-4

###### Comparison of disease severity and treatment outcomes between SSNHL patients with low and high IMT.

![](peerj-08-9276-g004)

                                         Low IMT (\<0.65 mm) (*n* = 22)   High IMT (≥0.65 mm) (*n* = 25)   *P* Value
  -------------------------------------- -------------------------------- -------------------------------- -----------
  PTA in affected ear, mean (SD), dB     72.8 (22.8)                      72.1 (24.0)                      0.915
  WRS in affected ear, median (IQR), %   16 (0--93)                       64 (0--92)                       0.321
  Vertigo, *n* (%)                                                                                         
  Yes                                    12 (54.5%)                       8 (32%)                          0.119
  No                                     10 (45.5%)                       17 (68%)                         
  Hearing gain, mean (SD), dB            23.3 (22.6)                      24.2 (20.4)                      0.892
  WRS change, median (IQR), %            12 (0--74)                       8 (0--60.5)                      0.652
  Siegel's criteria (*n*, %)                                                                               
  Complete recovery                      5 (22.6%)                        6 (24%)                          0.696
  Partial recovery                       4 (18.2%)                        7 (28%)                          
  Slight recovery                        4 (18.2%)                        2 (8%)                           
  No improvement                         9 (41.0%)                        10 (40%)                         

**Note:**

IMT, intima-media thickness; PTA, pure tone average; dB, decibel; SD, standard deviation; WRS, word recognition score.

Discussion
==========

Diagnosed patients often ask about the cause of SSNHL. Unfortunately, there is a lack of tools that can detect auditory pathway injury, causing most SSNHL cases to be only suspected after taking clinical histories and examing risk factors. Gluco-metabolic, lipidic and coagulative data can identify vascular risk factors for SSNHL ([@ref-11]), but not all laboratory tests are cost-effective ([@ref-13]; [@ref-36]). Here, we show that the higher carotid IMT is associated with an increased risk of SSNHL.

Carotid Doppler ultrasonography is commonly used to evaluate carotid artery atherosclerosis, an independent risk factor for stroke and myocardial infarction ([@ref-3]). In recent years, SSNHL has been associated with stroke ([@ref-18]; [@ref-19]; [@ref-22]) and myocardial infarction ([@ref-17]). These associations and the high frequency of cardiovascular risk factors in SSNHL patients ([@ref-1]) suggest that SSNHL is closely linked to cardiovascular disorders. Since the carotid system is the most important vascular supply for cerebral perfusion, it is reasonable to hypothesize that carotid atherosclerosis is a risk factor for SSNHL. Two prior studies found an increase in carotid IMT in SSNHL patients ([@ref-25]; [@ref-28]). Likewise, we found a higher percentage of high-IMT (≥0.65 mm) subjects in the SSNHL group. In a previous study in Taiwan, the risk of atherosclerosis increased in subjects with carotid IMT \>0.5 mm ([@ref-32]). Our work reveals early atherosclerotic changes in the carotid arteries of SSNHL patients.

Both sex and age influence the development of atherosclerosis and cardiovascular diseases ([@ref-31]). We found that significantly more females with SSNHL had carotid IMT ≥0.65 mm compared to control group females, although the difference was not significant between SSNHL and control groups in the male subjects. This suggests that greater carotid IMT is a risk factor for female SSNHL patients. Our finding is in accordance with the results of a previous study that used mostly male subjects and found no significant difference in the carotid IMT of SSNHL and control groups ([@ref-8]). Recent studies have emphasized the influence of sex differences on cardiovascular risk factors ([@ref-2]). Females have smaller carotid arteries than males ([@ref-20]; [@ref-29]). Therefore, early atherosclerotic changes may influence the vascular systems of end-organs, such as the inner ear, in females more than in males.

Another possible explanation for the greater carotid IMT in female SSNHL patients is the loss of estrogen during and after menopause. We found that the proportion of females aged ≥50 years with high carotid IMT was significantly greater in SSNHL patients than in control subjects. This was not the case for females aged \<50 years. In Taiwan, the mean menopausal age is about 50 years ([@ref-6]). Therefore, early atherosclerosis during menopause may increase the risk of SSNHL. Estrogen has been found to have protective vascular effects, promoting vasodilation and exerting an antioxidative action that protects against vascular injury ([@ref-23]). Oxidative stress had been suggested as a risk factor for endothelial dysfunction and SSNHL ([@ref-5]; [@ref-8]; [@ref-27]). Menopausal females with high IMT may be more predisposed to endothelial dysfunction and SSNHL than low-IMT subjects. Because post-menopausal women experience more microvascular dysfunction, endothelial dysfunction contributing to ischemic heart disease affects post-menopausal women more than premenopausal women ([@ref-16]). Further studies with more subjects are required to clarify whether sex and age differences influence the effects of vascular factors and early atherosclerosis on SSNHL development.

To the best of our knowledge, this is the first study to explore the influence of carotid IMT on SSNHL treatment outcomes. We found no significant difference in treatment outcomes between the high- and low-IMT groups, evaluated either by hearing gain or using Siegel's criteria. This was in agreement with the findings of previous studies which found that cardiovascular risk factors and metabolic syndromes did not affect SSNHL prognosis ([@ref-7]; [@ref-9]). It is probable that audiological factors, including the extent of initial hearing loss, the time elapsed between hearing loss onset and treatment, and associated vertigo, affect treatment outcomes ([@ref-7]; [@ref-9]) more profoundly than carotid IMT. Although increased carotid IMT does not influence SSNHL prognosis, it is unclear whether early atherosclerosis increases the risk of stroke in SSNHL patients. The associations between SSNHL and stroke have been studied ([@ref-18]; [@ref-22]). Future studies should explore whether SSNHL patients (particularly postmenopausal females) with greater carotid IMT have a higher risk of stroke.

In 2014, the American Heart Association published guidelines for stroke prevention in females ([@ref-4]) since they exhibit more stroke risk factors than males, including obesity/metabolic syndrome, atrial fibrillation and migraines with auras. Our work emphasizes the importance of sex differences when considering SSNHL risk factors, including increased carotid IMT. Further prospective and populational studies may confirm whether postmenopausal women with increased carotid IMT have higher risks of SSNHL and stroke.

Our work has several limitations. First, this study is cross-sectional, not populational, so we could not estimate the associations between high carotid IMT and SSNHL in the total population. Second, we found a significant difference in high IMT frequency between SSNHL and control subjects when analyzing all, female, or older female subjects, but the relatively small number of females aged ≥50 years decreased our statistical power. Third, all control subjects underwent health examinations which may have detected higher proportions of cardiovascular risk factors than in the general population. For example, the prevalence of DM in our control group (12.1%) was higher than the prevalence in the general population (around 6%), as revealed by Taiwan's National Health Insurance database ([@ref-14]). Future large-scale, population-based, prospective cohort studies on SSNHL incidence in subjects with high carotid IMT could verify whether early atherosclerosis increases the risk of SSNHL.

Conclusions
===========

We found that carotid IMT was significantly associated with the risk of SSNHL, particularly in females aged ≥50 years, but not with treatment outcomes. Our findings provide insights for future studies on other large-scale prospective registries to assess the role of carotid IMT in SSNHL.
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